NHO Revive opens pre-approval access for Daraxonrasib in stage 4 pancreatic cancer

NHO Revive says it will launch an Expanded Access Protocol next week to let eligible stage 4 pancreatic cancer patients receive Daraxonrasib before FDA approval. The program is aimed at patients who have run out of current treatment options or cannot tolerate their existing therapy.

Why it matters: - The Expanded Access Protocol could give eligible stage 4 pancreatic cancer patients access to an investigational therapy when standard options are failing or no longer tolerable. - The program offers a path to treatment before Daraxonrasib receives potential FDA approval. - Expanded access can matter most for patients with serious or life-threatening disease who do not qualify for a clinical trial.

What happened: - NHO Revive announced an upcoming Expanded Access Protocol for Daraxonrasib. - The program is expected to begin next week. - Once active, NHO Revive will accept referrals from healthcare providers and inquiries from patients. - The protocol is intended for eligible stage 4 pancreatic cancer patients. - Access will continue until Daraxonrasib receives FDA approval or the program is discontinued.

The details: - Eligible patients must be unable to tolerate their current treatment or have disease progression on their current line of therapy, as determined by their treating physician. - Daraxonrasib is an investigational therapy and has not been approved by the FDA. - Expanded access, also called compassionate use, is designed for patients with serious or life-threatening conditions who may not qualify for an ongoing clinical trial. - Dr. Kailash Mosalpura, Medical Oncologist at Nebraska Hematology-Oncology, said the program reflects a commitment to helping patients access promising investigational therapies while the regulatory review process continues. - NHO Revive describes itself as a joint initiative between Nebraska Hematology Oncology and Revive Research Institute. - The organization points readers to more information. - Nebraska Hematology-Oncology says it has served Lincoln and surrounding communities since 1997. - Nebraska Hematology-Oncology says it has seven physicians, 13 advanced practice providers and more than 145 staff. - Nebraska Hematology-Oncology says it was the first QOPI-certified and Oncology Medical Home APC4-certified clinic in Nebraska. - The clinic says it is recognized as a cancer center meeting high standards for quality cancer care.

Between the lines: - The program appears designed to bridge a gap for patients with limited treatment options while regulatory review remains unresolved. - Because access depends on physician evaluation and protocol requirements, the pool of eligible patients will be narrow. - The announcement also positions NHO Revive as a research and treatment access partner, not just a care provider.

What's next: - NHO Revive expects to start taking referrals and patient questions once the protocol activates next week. - Physicians will determine whether individual patients meet inclusion criteria. - Daraxonrasib remains available through the protocol only until FDA approval or termination of the program.